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Cardiomyocyte Functional Etiology in Heart Failure With Preserved
Ejection Fraction Is Distinctive—A New Preclinical Model
Claire L. Curl, PhD; Vennetia R. Danes, MD, PhD; James R. Bell, PhD; Antonia J. A. Raaijmakers, MSc; Wendy T. K. Ip, PhD;
Chanchal Chandramouli, PhD; Tristan W. Harding, MD; Enzo R. Porrello, PhD; Jeffrey R. Erickson, PhD; Fadi J. Charchar, PhD;
Andrew R. Kompa, PhD; Amanda J. Edgley, PhD; David J. Crossman, PhD; Christian Soeller, PhD; Kimberley M. Mellor, PhD;
Jonathan M. Kalman, MD; Stephen B. Harrap, MD, PhD; Lea M. D. Delbridge, PhD
Background-—Among the growing numbers of patients with heart failure, up to one half have heart failure with preserved ejection
fraction (HFpEF). The lack of effective treatments for HFpEF is a substantial and escalating unmet clinical need—and the lack of
HFpEF-speciﬁc animal models represents a major preclinical barrier in advancing understanding of HFpEF. As established
treatments for heart failure with reduced ejection fraction (HFrEF) have proven ineffective for HFpEF, the contention that the
intrinsic cardiomyocyte phenotype is distinct in these 2 conditions requires consideration. Our goal was to validate and
characterize a new rodent model of HFpEF, undertaking longitudinal investigations to delineate the associated cardiac and
cardiomyocyte pathophysiology.
Methods and Results-—The selectively inbred Hypertrophic Heart Rat (HHR) strain exhibits adult cardiac enlargement (without
hypertension) and premature death (40% mortality at 50 weeks) compared to its control strain, the normal heart rat. Hypertrophy
was characterized in vivo by maintained systolic parameters (ejection fraction at 85%–90% control) with marked diastolic
dysfunction (increased E/E0). Surprisingly, HHR cardiomyocytes were hypercontractile, exhibiting high Ca2+ operational levels and
markedly increased L-type Ca2+ channel current. In HHR, prominent regions of reparative ﬁbrosis in the left ventricle free wall
adjacent to the interventricular septum were observed.
Conclusions-—Thus, the cardiomyocyte remodeling process in the etiology of this HFpEF model contrasts dramatically with the
suppressed Ca2+ cycling state that typiﬁes heart failure with reduced ejection fraction. These ﬁndings may explain clinical
observations, that treatments considered appropriate for heart failure with reduced ejection fraction are of little beneﬁt for HFpEF
—and suggest a basis for new therapeutic strategies. ( J Am Heart Assoc. 2018;7:e007451. DOI: 10.1161/JAHA.117.007451.)
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Among the growing numbers of patients with heart failure,as many as one half have heart failure with preserved
ejection fraction (HFpEF), and clinical trials have yet to deﬁne
an effective and speciﬁc treatment for this condition.1,2 The
pathophysiology of HFpEF is characterized by near normal
systolic function coincident with diastolic dysfunction and
inadequate ventricular ﬁlling at normal pressures. Surpris-
ingly, while there has been considerable focus on reﬁning
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differential diagnostic criteria for HFpEF relative to heart
failure with reduced ejection fraction (HFrEF), an understand-
ing of the cardiomyocyte functional phenotype that charac-
terizes HFpEF is lacking. The lack of HFpEF-speciﬁc animal
models represents a major preclinical barrier in advancing
understanding of HFpEF.3 Deﬁning the cellular basis of HFpEF
dysfunction is critical for guiding the development of new
treatments for this failure condition.4
Although the HFpEF phenotype is not homogenous,2,5,6
cardiac hypertrophy is considered an important diagnostic
element, and the extent of hypertrophy is a key prognostic
indicator in HFpEF.7,8 Hypertension (although often present as
a comorbidity to a variable extent in different HFpEF
populations) has not been identiﬁed as a baseline discrimi-
nator in determining the development of HFpEF in outcome
trials.9 In addition to hypertrophy, heart failure guidelines also
recognize other diagnostic features of HFpEF, including
increased left ventricular ﬁlling pressures, normal left ventric-
ular end-diastolic volume, and ﬁbrosis.7,8,10 Systemic inﬂam-
matory involvement and metabolic disturbances linked with
comorbidities may also contribute.9
In HFrEF, the cellular “remodeling” processes generally
understood to characterize the progression to failure include
reduced cardiomyocyte contractile response, diminished
systolic Ca2+ activator availability, and dysregulated sar-
coplasmic reticulum (SR) Ca2+ store operation.11 This general
etiology is inferred primarily from experimental observation of
tissues and myocytes of various animal models of systolic
dysfunction occurring as a result of abnormal volume or
pressure loads and some studies of end-stage failing human
myocardium.12 Cell-directed treatments for HFrEF have
principally focused on interventions to augment availability
or actions of cardiomyocyte activator Ca2+.13 These HFrEF
therapies, which have largely relied on neurohumoral
approaches involving angiotensin, aldosterone, and b-adreno-
ceptor targets, have not been successful in the HFpEF
context,3,14 raising questions about the cardiomyocyte phe-
notypes in HFpEF.
There is a poor understanding of the cardiomyocyte
pathophysiology of HFpEF, in large part because of the
limited availability of appropriate HFpEF preclinical models.
Indeed, this problematic lack of animal models has recently
been highlighted as a major barrier in the progression of
preclinical mechanistic work available to inform new thera-
peutic directions for HFpEF.3 Proposed models generally
involve pressure overload interventions, with secondary
development of diastolic dysfunction, and do not fully
recapitulate clinical features.15 The cardiomyocyte HFpEF
functional characteristics, wherein the intrinsic pathologic
trigger is not a systolic loading challenge, could be expected
to be very different from the HFrEF myocyte phenotype. There
are no studies of intact HFpEF-derived cardiomyocytes
(human or animal) from disease settings involving primary
cardiac pathology. Findings from membrane disrupted cell
preparations derived from the myocardium of patients with
diastolic heart failure have described sarcomeric structures
exhibiting increased passive force response to stretch—but
there has been no investigation of intact cardiomyocyte Ca2+
handling and contractile responsiveness in the HFpEF
setting arising from underlying myocardial hypertrophic
pathogenesis.
Here, we report and validate a novel rodent model of
HFpEF—which exhibits cardiac hypertrophy and premature
mortality independent of hemodynamic loading.16,17 In the
hypertrophic heart rat strain (HHR), we demonstrate that the
in vivo progression to diastolic failure (with preservation of
systolic performance) is accompanied by unexpected hyper-
function of cardiomyocytes with elevated systolic activator
Ca2+ availability and contractile response. Molecular and
electrophysiologic analyses identify arrhythmogenic cellular
substrates. Thus, the cardiomyocyte remodeling process in
the etiology of this HFpEF model contrasts dramatically with
that seen in the HFrEF state. These ﬁndings may explain
clinical observations that intervention strategies considered
appropriate for HFrEF are of little beneﬁt for HFpEF. New
insights from our unique animal model of HFpEF provide
opportunities to develop novel and targeted HFpEF therapeu-
tic approaches.
Clinical Perspective
What Is New?
• Heart failure with preserved ejection fraction (HFpEF) is a
condition for which there is no speciﬁc treatment.
• The lack of HFpEF-speciﬁc animal models represents a
major preclinical barrier in advancing understanding of
HFpEF.
• We validate and characterize a new rodent model of HFpEF,
undertaking longitudinal investigations to delineate the
associated cardiac and cardiomyocyte pathophysiology.
• Surprisingly, HHR cardiomyocytes were hypercontractile,
exhibiting high Ca2+ operational levels and markedly
increased L-type Ca2+ channel current.
What Are the Clinical Implications?
• The cardiomyocyte remodeling process in the etiology of
this HFpEF model contrasts dramatically with the sup-
pressed Ca2+ cycling state that typiﬁes heart failure with
reduced ejection fraction.
• These ﬁndings may explain clinical observations that
treatments considered appropriate for heart failure with
reduced ejection fraction are of little beneﬁt for HFpEF—
and suggest a basis for new therapeutic strategies.
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Methods
The data, analytic methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure on reasonable request.
Detailed methods are available in Data S1.
Experimental Animals
A novel normotensive, hypertrophic rat strain generated
through selection and cross breeding of Fischer 344 and
spontaneously hypertensive rat strain progenitors has previ-
ously been described.16,17 Brieﬂy, initial spontaneously
hypertensive rat genomic analysis had identiﬁed blood
pressure–independent, hypertrophic genetic loci.18 Selection
for large and small echocardiographic heart size and low
blood pressure was used to derive simultaneously the
hypertrophic heart rat (HHR) and its control, the normal heart
rat (NHR), respectively,16 now beyond the F50 generation of
inbreeding. The HHR constitutes a polygenic model of
spontaneous cardiac hypertrophy with a natural disease
history. Experiments were performed using male HHR and
NHR at the failure and prefailure ages speciﬁed below.
Normotension in HHR and NHR has been demonstrated
previously,16 and here equivalent diurnal mean arterial
pressures were conﬁrmed telemetrically (Figure S1A).
All experimental animals were housed under a 12-hour
light/dark cycle with water and standard chow provided
ad libitum. All investigations were undertaken in accordance
with the National Health and Medical Research Council/
Commonwealth Scientiﬁc and Industrial Research Organisa-
tion/ACC Australian Code of Practice for the Care and Use of
Animals for Scientiﬁc Purposes (1997), as approved (Univer-
sity of Melbourne Animal Ethics Committee).
Echocardiography, Electrocardiography, and
Hemodynamic Measurements
Echo- and electrocardiography were performed under light
anesthesia (inhalation of isoﬂurane at 1.5%). Cardiac structure
and systolic and diastolic function were evaluated by
transthoracic 2-dimensional B- and M-mode and blood ﬂow
and tissue Doppler echocardiography (GE Vivid 9; 15 mHz
i13L linear array transducer). Acquisition and ofﬂine analysis
was performed with GE EchoPac software. ECGs were
obtained using external clip leads in standard conﬁguration.
Ambulatory 24-hour blood pressure measurements were
made using implanted devices to record from the
intra-abdominal aorta (TA11PA-C40, DSI). To perform left
ventricular catheterization, animals were anesthetized with
sodium pentobarbital (60 mg/kg), intubated and ventilated,
and a 2F miniaturized combined conductance catheter-
micromanometer (Model SPR-838 Millar instruments, Hous-
ton, TX) was inserted into the right carotid and advanced into
the left ventricle until stable pressure-volume loops were
obtained. Data were acquired under steady-state conditions
and during preload reduction.
Using the pressure conductance data, a range of functional
parameters was then calculated including end-diastolic pres-
sure, maximum rate of pressure change in the ventricle (+dP/
dt max), minimum rate of pressure change in the ventricle
(dP/dt min) and the slope of the end-diastolic pressure
volume relationship.
Histologic Analysis of Myocardial Collagen
Content and Confocal Analysis of Cardiomyocyte
Ultrastructure
To evaluate collagen histology, hearts were ﬁxed in 10%
formalin for histologic analysis using picrosirius red as
previously described.19 Images were captured with brightﬁeld
microscopy using the Zeiss Imager D1, connected to a Zeiss
AxioCam MRc5 color camera and using AxioVision 40 version
4.7.1.0 acquisition software (Zeiss, Germany) with 10 images
per section, from 2 sections per heart. Image analysis was
performed using Image Pro Plus (V4.5.1, Media Cybernetics,
Bethesda, MD) in a “blinded” manner. For ultrastructural
analysis to examine cardiomyocyte sarcomeric integrity, high-
resolution confocal microscopy was performed on ﬁxed
tissues labeled with the ﬂuorescent marker wheat germ
agglutinin to delineate cardiomyocyte T-tubule geometry using
a Zeiss LSM410 confocal microscope and 963 NA 1.25 oil-
immersion objective. The t-tubule images were converted to
frequency space using fast Fourier transform, and the peak in
the power spectrum corresponding to the sarcomere spacing
was estimated by Gaussian ﬁt (“T power”).
Cell Isolation and Cardiomyocyte Morphology
NHR and HHR single ventricular myocytes were isolated
enzymatically using methods previously described.19,20
Brieﬂy, hearts were removed and perfused retrogradely on a
Langendorff apparatus with Ca2+-free bicarbonate-buffered
physiologic saline solution, maintained at 37°C, with the
following composition (mmol/L): NaCl, 118; KCl, 4.8; KH2PO4,
1.2; MgSO4, 1.2; NaHCO3, 25, glucose, 11. Following
20 minutes of 0.45 mg/mL collagenase (Worthington, Type
II) perfusion, hearts were removed from the perfusion
apparatus, the left ventricle was isolated and placed in a
conical ﬂask, and myocytes were dispersed by gentle
agitation. Fractions containing viable cells were resuspended
at room temperature in 2 to 3 mL of HEPES-buffered
physiologic saline containing 1 mmol/L Ca2+ and were stored
at room temperature. Cells were used within 8 hours.
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Whole-Cell Patch Clamp
Voltage-gated Ca2+ currents (I-Ca) and Na+/Ca2+ current
(I-NCX) were measured using a whole-cell voltage clamp
(Axopatch 200B, Digidata 1200B, Axon Instruments) with 1 to
3 MΩ pipette resistances (TW150F-3, World Precision Instru-
ments). For ICa, voltage step protocols with 3 holding
potentials were applied: 115, 90, and 50 mV. For INCX,
a combined voltage step and ramp protocol from holding
potential 90 mV to 45 mV to 0 mV to +80 mV to
140 mV was implemented. Current analysis procedures
were performed using Clampﬁt (pClamp8).
Cardiomyocyte Intracellular Ca2+ and
Contractility Measurements
Intracellular Ca2+ and cell length were measured simultane-
ously by microﬂuorimetry and edge detection (IonOptix). Cells
were fura-2/AM-loaded (2.5 lmol/L, 20 minutes, Molecular
Probes), superfused with HEPES-Krebs buffer and ﬁeld
stimulated. Cardiomyocyte performance was evaluated under
basal paced conditions (37°C, 3 Hz, 1.5 mmol/L Ca2+),
during a rest interval (37°C, 1.5 mmol/L Ca2+ 3 Hz for
5 minutes, stimulator off 30 seconds), with different inotropic
challenges (4 mmol/L Ca2+, isoproterenol 108 mol/L and in
response to rapid caffeine spritz to evaluate SR load (Ca2+
transient only).
Immunoblotting
Left ventricular tissue was homogenized and nonfractionated
homogenates were reconstituted in sodium dodecylsulphate
sample buffer. Equal volumes were loaded onto polyacry-
lamide gels for electrophoresis and immunoblot analysis.
Antibody usage is tabulated in Figure S2A.
Statistical Analyses
In general (unless otherwise stated) data are presented as
meanSEM. Comparisons between two groups with normally
distributed data were performed with Student unpaired t test.
Data from experiments with two groups assessed at multiple
points were evaluated by a one-way ANOVA with repeated
measures. Two-way ANOVA was used for evaluation of data
groups comprising 2 factors. Correlation analyses were
performed to determine the Pearson coefﬁcient within each
strain and signiﬁcance values evaluated. Data are shown
depicting linear regression plots for each strain (SPSS c21.0;
Graph Pad Prism V6). Data analysis was performed in a
blinded manner. Survival (Kaplan–Meier) data were analyzed
by log-rank Mantel-Cox test. Differences were considered
signiﬁcant at P<0.05 (SPSS v.21.0; Graph Pad Prism V6).
Results
Premature Mortality, Hypertrophy, and Diastolic
Dysfunction With Preserved Systolic Function in
the HHR
HHR and NHR cohorts were tracked longitudinally to
characterize the functional and structural development and
consequences of hypertrophy. HHRs died prematurely (pri-
mary end point) with a 40% mortality by 50 weeks of age
compared with 0% NHR mortality (Figure 1A). Of those
animals aged to end point or requiring euthanasia due to
acute symptomatic deterioration, 40% exhibited pulmonary
edema (lung weight index HHR 5.690.8 versus NHR
3.750.1, P<0.05). Other animals exhibited sudden prema-
ture death. Cardiac weight index at autopsy was substantially
elevated (Figure 1B). In vivo function and structure was
measured by echocardiography at 50 weeks (cohort surviv-
ing) and at 30 weeks (full cohort). Hemodynamic measures
using cardiac catheterization were also obtained from a
cohort of 50-week animals (Table S1, Figure S1B and S1C).
HHR ejection fraction was substantially preserved at 85% to
90% NHR level at 50 and 30 weeks, respectively (Figure 1C
and 1D, Table S1). While these 10% to 15% differences could
be resolved statistically, the systolic performance levels could
be considered to be relatively preserved. In the clinical
setting, the maintenance of ejection fraction at 85% to 90% of
normal value would be identiﬁed as “preserved” and consid-
ered a diagnostic element in establishing HFpEF occurrence.
Maintained systolic function in HHRs was evident in the
absence of signiﬁcant dilation (diastolic chamber dimension),
while systolic chamber dimension changes matched ejection
fraction maintenance at 85% to 90% NHR value (Figure 1E,
Table S1). Diastolic dysfunction at 30 and 50 weeks was
evident in HHRs with markedly elevated E/E0 (Figure 1F,
Table S1) which was consistent with signiﬁcantly increased
end-diastolic pressure-volume relationship measurement
from pressure-volume loop analysis (Figure S1B and S1C).
HHR tachycardia was apparent, consistent with progression
to failure (Figure 1G, Table S1). Thus, HHRs exhibited
premature mortality, preserved ejection fraction, and sub-
stantially degraded diastolic performance relative to controls
(ie, HFpEF). Interestingly, evaluation of very young HHR
cohorts showed the emergence of diastolic dysfunction early,
with maximal systolic function (Figure S3).
Histologic analyses in the 50-week HHRs revealed the
presence of dispersed focal ﬁbrotic areas in the extracellular
matrix that did not follow a typical perivascular localization.
The regions of most prominent occurrence of ﬁbrotic foci
were mapped to the transverse midwall area of the left
ventricle adjacent to the interventricular septum and the area
of septal free wall conﬂuence (Figure S4). Although the overall
ﬁbrotic load in HHR was signiﬁcantly greater than NHR
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(Figure 2A through 2E), when focal areas were excluded, the
interstitial matrix histology was similar in HHRs and NHRs.
Thus, this failure-associated histology comprised focal ﬁbrotic
regions indicative of localized reparative responses.
Progression to failure has been linked with loss of
cardiomyocyte T-tubule structural integrity, understood to
compromise excitation-contraction coupling efﬁcacy. Despite
the very marked cardiomyocyte size increase, ultrastructural
analyses found no evidence of T-tubule structural disturbance
in HHR myocytes. Morphologically, there was no evidence of
T-tubule spatial dispersion. The wheat germ agglutinin–
stained myocytes were similar for HHRs and NHRs, conﬁrming
the absence of signiﬁcant changes in the T-system morphol-
ogy (Figure 2F through 2I).
Cardiomyocyte Hypercontractility Characterizes
Progression to Failure With Preserved Systolic
Function
Electromechanical performance of fura-2 loaded isolated
cardiomyocytes obtained from HHR and NHR hearts at age
20 to 30 weeks was evaluated, a prefailure time point
selected as a disease progression stage before emergence of
premature mortality in HHR. This was considered a time point
at which the most consistent phenotypic information could be
obtained about the status of electromechanical coupling
priming the HHR for failure, and when cardiomyocyte isolation
yield could be most reproducible.
HFpEF in the HHR was associated with signiﬁcant
cardiomyocyte enlargement (Figure 3A and 3B, Table S2)
determined microscopically from single myocyte dimensions
and electrophysiologically by membrane capacitance. Radial
and longitudinal cell dimensions were increased similarly
(>20%). Thus, hypertrophy at organ and cellular levels was
established in the HHR. Functional analysis of shortening
performance in isotonically contracting isolated intact car-
diomyocytes revealed a dramatic HHR “hypercontractile”
state, with almost doubled maximum shortening and short-
ening kinetic measures allowing overall maintenance of cell
activation cycle timing (Figures 3C, 3E, and 4A through 4C).
Interestingly, this in vitro hypercontractility was consistent
with in vivo hemodynamic measurements obtained using
cardiac catheterization (on 50-week animals only), where the
maximal rate of pressure development in the HHR was
increased (Table S1). HHR myocyte responses to in vitro
inotropic intervention (elevated Ca2+, b-stimulation) were
modestly potentiated (Figure 4E through 4H).
HHR myocyte diastolic Ca2+ levels were elevated and
transient amplitude values increased (Figure 3D, 3F, and 3G).
Positive correlations between HHR myocyte size and Ca2+
levels (but not shortening responses) were detected (Fig-
ure 3H through 3J), suggesting a hypertrophy-dependent
phenomenon of Ca2+ load augmentation. For individual
activation cycles, myocyte-shortening Ca2+ “phase-loop” plots
were constructed. During the relaxation phase, the descend-
ing portion of the loop provides a dynamic index of
myoﬁlament Ca2+ sensitivity. A right shift in HHR myocyte
loop relaxation phase provided evidence of decreased myoﬁl-
ament Ca2+ responsiveness in the hypertrophic myocytes,
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Figure 1. Premature mortality, hypertrophy, and diastolic dys-
function with preserved systolic function in the hypertrophic heart
rat (end point age 50 weeks, prefailure 30 weeks). A, Survival,
normal heart rat (NHR, dashed line) and hypertrophic heart rat
(HHR, solid line). B, Postmortem cardiac weight index (mg/g).
(50 weeks). C, Exemplar M-mode echocardiographs HHR vs NHR
hearts, and exemplar blood ﬂow and tissue Doppler images
(50 weeks). D, Preserved systolic function in HHR with minimal
decrement of ejection fraction (EF). E, Left ventricular internal
diameter (diastole) (LVIDd). F, Diastolic function—E/E0. G, Heart
rate (HR, bpm). Graphs show mean  SEM. For A, *P=0.0004
(log-rank Mantel-Cox test), for B and D through G, *P<0.05
(Student t test, n=6–10 hearts/group).
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Figure 2. Extracellular matrix disrupted by ﬁbrotic foci with progressing HFpEF, yet maintained cardiomyocyte
ultrastructural integrity (50 weeks). A through C, Picrosirius red collagen histology. Fibrotic foci hypertrophic
heart rat (HHR), interstitial ﬁbrosis normal heart rat (NHR) and HHR. D and E, Fibrosis densitometry: total and
interstitial excluding focal areas in HHR. F and G, T-tubule labeling with wheat germ agglutinin Alex-594 shows t-
system geometry regularity in sectioned myocardium of HHR and NHR. H and I, Depiction of T-tubule power vs
spatial frequency in longitudinal dimension for HHR and NHR evidenced high level of T-tubule structural integrity in
HHR and NHR. Graphs show mean  SEM. For D and E, Student t test, n=20 images/N=5 hearts. For F and G,
n=18/group; N=3 hearts/group.
DOI: 10.1161/JAHA.117.007451 Journal of the American Heart Association 6
Cardiomyocyte Functional Etiology of HFpEF Curl et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 28, 2019
644.2 644.41.0
1.2
1.4
Female n3 Ca
67.699997 67.799995 67.899994
1.4
1.6
1.8
2.0
2.2
9
0
m
80 ms
NHR
HHR
% Shortening
Myocyte Volume
NHR
HHR
Fu
ra
2
(A
rb
 u
ni
ts
)
100 ms
1
0
Diastolic Ca2+ Amplitude Ca2+
% Shortening Diastolic Ca2+ Systolic Ca2+
*
E G
DC
A B
F
H JI
LK
NHR HHR
Ca2+ Phase Loop Ca2+ at 50% 
relaxaon
Figure 3. HHR cardiomyocyte hypercontractility characterizes progression to failure with preserved
systolic function (20–30 weeks). A, Bright ﬁeld normal heart rat (NHR) and hypertrophic heart rat
(HHR) cardiomyocyte micrographs. B, Mean computed cardiomyocyte volume from 2-dimensional
isolated myocyte measurements (n=mean 50 cells for N=16–22 hearts). C and D, Fura-2 loaded
isolated myocyte exemplar records: shortening and Ca2+ transients. E through G, Cardiomyocyte
mean maximum % shortening (normalized for myocyte length), and mean Ca2+ diastolic and twitch
amplitude levels (n=16–17 cells for N=10 hearts/group). H through J, Regression plots: myocyte size
(lm) vs % shortening, diastolic Ca2+ and peak systolic Ca2+ levels (n=16–17 cells from N=10 hearts/
group). K and L, Exemplar “Phase-loop” plots of cardiomyocyte length vs Ca2+ during activation cycle
show HHR right-shift, with signiﬁcantly higher Ca2+ at 50% myocyte relaxation, indicating reduced
sensitivity to Ca2+ levels (n=16–17 cells from N=10 hearts/group). Graphs showmean SEM, For B,
E through G, and L, *P<0.05 (Student t test). For H through J, P value, Pearson’s correlation.
DOI: 10.1161/JAHA.117.007451 Journal of the American Heart Association 7
Cardiomyocyte Functional Etiology of HFpEF Curl et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 28, 2019
quantiﬁed by measurement of Ca2+ at 50% myocyte relaxation
(Figure 3K and 3L).
No differences in HHR and NHR isoform type and total
phosphorylation status of titin (an extensible protein with a
role in determining sarcomeric stiffness) were identiﬁed
(Figure S5, Table S3).
Elevated Myocyte Ca2+ Loading in Diastolic
Dysfunction Linked With Increased I-Ca2+ Current
Density
I-Ca measured using whole-cell patch clamp methodology,
were signiﬁcantly elevated in prefailure HHR myocytes relative
to NHR (holding potential 90 mV), with peak I-Ca density
(normalized for cell size) increased by 65% in HHRs
(Figure 5A through 5C). Current measured from 90 mV
substantially comprises the L-type Ca2+ current. Consistent
current density differences were also observed for current
ensembles measured from holding potentials 50 and
115 mV. There was no evidence of HHR-speciﬁc low-
voltage activated currents (absence of inﬂexion in current
plots from 115 and 90 mV holding potentials) (Figure S6).
Capacity for Ca2+ ﬂux via the Na+/Ca2+ exchanger was
examined electrophysiologically, as this transporter upregula-
tion is implicated in arrhythmogenicity.21 In forward mode
operation (ie, Ca2+ extrusion, inward current, from 90 mV)
and reverse mode operation (to +40 mV), the I-NCX densities
(pA/pF) were not different for NHR and HHR (Figure 5D
through 5F). Protein expression data indicate that NCX1 levels
are also not different in the NHR and HHR (Figure S7).
HHR In Vivo and In Vitro Dysrhythmic Substrates
—Cardiomyocyte Ca2+ Handling Instability
In vivo occurrence of prominent arrhythmic episodes in HHR
at 20 to 30 weeks and beyond was conﬁrmed by external lead
ECG—events not observed in NHR (Figure 6A). Signiﬁcant
prolongation of mean HHR QRS interval was quantiﬁed,
consistent with ventricular abnormality (Figure S8). Elec-
tromechanical instability in isolated HHR cardiomyocytes was
also quantiﬁable, with a 2-fold increase in occurrence of
spontaneous SR Ca2+ release events (Figure 6B) indicative of
SR Ca2+ store overload susceptibility. Regulation of activator
Ca2+ and SR Ca2+ load stability is crucially dependent on
expression and activation levels of key proteins involved in SR
Ca2+ uptake and release. In the HHR, total expression levels
of the SR Ca2+ ATPase (SERCA2a), phospholamban (the
SERCA2a negative regulator), and the SR Ca2+ release
channel protein were signiﬁcantly reduced. In contrast, the
phosphorylation states of these proteins were markedly
increased—effects that act to relieve SR pump inhibition
and promote SR Ca2+ release channel trigger sensitivity and
leak (Figure 6C and 6D). Expression-level reduction and
increased activation status of the upstream regulator Ca2+-
Max Rate  
Lengthening 
Max Rate  
Shortening Time to Peak Transient Decay - Tau
    
    % Shortening  
(4mM Ca2+) 
Max Rate  
Shortening 
(4mM Ca2+) 
% Shortening  
(10-8M Isop) 
Time to Peak  
(10-8M Isop) 
A CB
E G HF
D
Figure 4. Isolated cardiomyocyte basal shortening parameters and responses to inotropic interventions
(20–30 weeks). A through D, Mean maximum rate of shortening, time of peak shortening, maximum rate of
lengthening and Ca2+ transient decay time constant (s=1/e). E and F, Mean changes in shortening (%S) and
maximum rate of shortening in response to an increase in superfusate [Ca2+] from 1.5 to 4 mmol/L for
normal heart rat (NHR) and hypertrophic heart rat (HHR). G and H, Mean changes in shortening (%S) and
time to peak shortening in response to isoproterenol treatment (108 mol/L) for NHR and HHR. Graphs
show mean  SEM. For each myocyte group, reference performance level under control pretreatment
conditions designated 100%. (*P<0.05, Student t test, n=17 to 19 cells from N=4 to 6 hearts/group).
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calmodulin dependent kinase II (CaMKII) was observed
(Figure 6E), consistent with increased activation of the SR
Ca2+ effector CaMKII target proteins. Evidence indicates that
SERCA2 activity is increased on the basis of hyperphospho-
rylation of the SR pump regulator phospholamban (Figure 6C)
and more rapid rate of transient decay in the HHR (Figure 4D).
Pilot caffeine spritz experiments also indicate SR Ca load is
elevated in the HHR (Figure S9).
Discussion
In this study, we present and characterize a new experimental
model of HFpEF—and identify a cardiomyocyte pathology that
contrasts conspicuously with that generally reported in HFrEF
conditions. In vivo, the HHR displays marked diastolic
dysfunction in the context of relatively preserved systolic
function. The in vitro cardiomyocyte functional studies of Ca2+
handling and shortening performance surprisingly reveal a
hypercontractile state underlying the in vivo diastolic dys-
function. Other notable features include those of focal and
relatively discrete areas of interstitial ﬁbrosis and the in vivo
predisposition to dysrhythmia and sudden death. The car-
diomyocyte phenotypes of higher incidence of spontaneous
Ca2+ transients and molecular changes consistent with SR
Ca2+ instability provide evidence of cellular arrhythmogenic
substrate. Thus, preservation of EF is apparently achieved
through hypercontractility, which compensates for cardiomy-
ocyte deﬁcit and structural slippage at ﬁbrotic foci. These
ﬁndings represent a potentially important advance in under-
standing the cellular etiology of HFpEF. We demonstrate that
the cardiomyocyte Ca2+ handling and contractile abnormali-
ties in HFpEF are fundamentally different to the cellular
electromechanical features usually observed in association
with HFrEF.
The HHR provides a model that closely reﬂects clinical
HFpEF. We have previously identiﬁed early emergence of
cardiac hypertrophy in adult HHR, linked with deﬁcient
cardiomyocyte endowment in the neonatal heart.16,17 Now
in this longitudinal study, we demonstrate that hypertrophic
progression to failure occurs with animal aging and without
additional intervention. At failure, diastolic dysfunction is
marked, while ejection fraction and fractional shortening are
largely maintained, with normal end-diastolic volume index.
We show that premature mortality in the HHR is associated
with evidence of ventricular stiffness as indexed by elevated
end-diastolic pressure-volume relationship (EDPVR) and
impaired ﬁlling, focal reparative (interstitial) ﬁbrosis, and
prominent cardiomyocyte hypertrophy. Elevated brain natri-
uretic peptide has been shown previously.17 Together, these
ﬁndings indicate the HHRs die prematurely from both fatal
cardiac arrhythmias and chronic diastolic heart failure. This
constellation of phenotypes is consistent with generally
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Figure 5. Elevated myocyte Ca2+ loading in diastolic dysfunction linked with increased I-Ca current
density (20–30 weeks). A, I-Ca voltage clamp protocol, holding potential 90 mV. B, Representative I-Ca
current traces. C, Mean I-Ca current densities (pA/pF). D, Na+/Ca2+ exchange current (I-NCX) voltage
clamp protocol and representative current traces, I-NCX quantiﬁcation by current subtraction 5 mmol/L
NiCl2. E, Mean normalized I-NCX determined at ramp test potentials 140 to +40 mV. F, Mean maximum
inward I-NCX density (inward and outward mode operation). Graphs show mean  SEM (*P<0.05, 1 way
ANOVA with repeated measures, n=27–30 cells for N=9 hearts/group).
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accepted clinical benchmarks for HFpEF diagnosis—notwith-
standing the inherent syndrome heterogeneity.7–9
HHR cardiomyocytes exhibit hypercontractile status and
high Ca2+ operational levels linked with arrhythmogenic
vulnerability. These cardiomyocyte operational characteristics
contrast dramatically with the canonical view of the hypertro-
phied and failing cardiomyocyte—a phenotype of HFrEF deﬁned
primarily in the setting of hemodynamic loading and typiﬁed by
impaired contractility and reduced activator Ca2+ availability.11
Systolic function preservation in the HHR likely derives from the
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cardiomyocytes, quantiﬁed over 30 seconds. (*P<0.05, Student t test, n=21–23 cells/group). C
through E, Immunoblot analyses of total protein expression and phosphorylation levels, left
ventricular tissue homogenate, for SERCA2a, PLB (Ser-17), RYR2 (Ser2814), CaMKII (combined dB &
dC isoform, Thr287) (*P<0.05, Student t test, N=10 hearts/group). Graphs show mean  SEM. For
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large increase in density of the L-type Ca2+ channel, underpin-
ning cardiomyocyte hypercontractility. The developmental
mechano-transduction link between increased myocyte dimen-
sion and hyperperformance is unknown but appears to be a
characteristic speciﬁc for pathologic myocyte enlargement as
expressed in the HHR. In HHRs there was a signiﬁcant and
positive correlation of cell dimension with systolic and with
diastolic Ca2+ levels (ie, larger myocytes exhibited more
elevation in Ca2+ operational levels). This relationship was
absent in the NHR. This ﬁnding supports the speculation that a
signaling processmay operate to link hypertrophy induction and
shift of Ca2+ operational levels in the evolving HFpEF context.
Temporally and spatially averaged elevations in cardiomyocyte
Ca2+ levels have been linked with induction of experimental
hypertrophy.22 Elevated Ca2+ levels have been observed in
ventricular biopsy specimens of patients diagnosed with
hypertensive heart disease exhibiting HFpEF symptoms (in the
absence of any disturbance of Na+ perturbation).23 Furtherwork
is required to evaluate the myocyte hypertrophy-Ca2+ relation-
ship and potential interventional opportunities speciﬁcally in the
HFpEF setting. In the HHR, we also found an indirect indication
of myoﬁlament Ca2+ desensitization—this may suggest a
protective adaptation in response to the high Ca2+ cycling
environment. In the HHR, it will be etiologically informative to
conﬁrm that the elevated Ca2+ transient phenotype persists to
point of failure, and further longitudinal studies are required.
It may be hypothesized that the cardiomyocyte deﬁcit in
HHR mediates compensatory hypertrophy of surviving myo-
cytes through mechano-transduced shifts in molecular man-
agement of Ca2+ inﬂux. Increased voltage-activated Ca2+
current was linked with both increased Ca2+ transient
amplitude and peak myocyte shortening. Our data do not
allow quantitative dissection of the Ca2+ channel/SERCA2
contributions to the transient but do support the proposition
that the increased L-type Ca2+ channel current provides the
primary driver for elevated Ca2+ transient, and a consequen-
tially activated SERCA2 allows for enhanced SR Ca2+
releasable load. Further experimental work with cardiomy-
ocytes using pharmacologic agents is required to resolve
these questions, including longitudinal studies that examine
the early emergence of the Ca2+ channel phenotype.
Notably, no functional difference in Na+/Ca2+ current
density was detected between HHR and NHR cardiomyocytes.
This contrasts with previous experimental demonstration of
Na+/Ca2+ exchanger upregulation as a key process in
transition to failure in HFrEF.21 These ﬁndings also differ
from observations made in a setting of diastolic dysfunction
where the primary insult is acute renal intervention (nephrec-
tomy) and cardiomyocyte systolic Ca2+ levels and contractility
are unchanged.24 Protein expression data indicate that NCX1
levels are also not different in the two strains. Thus, an
explanation of increased activation of the NCX in HHR seems
likely, to ensure balance between Ca2+ inﬂux/efﬂux. NCX
activity is known to be allosterically regulated by intracellular
Ca2+. There is also evidence of regulation of exchanger
activity by protein posttranslation modiﬁcation—either
directly or by accessory protein (eg, phospholemman) mod-
iﬁcation. A comprehensive understanding of the manner in
which posttranslational modiﬁcations regulate NCX has yet to
be resolved.
The notion that early development myocardial stress
events independent of systemic load may be involved in
hypertrophy initiation is consistent with evidence that dias-
tolic dysfunction in the spontaneously hypertensive rat is
detectable before onset of hypertrophy and hypertension.25
Our ﬁnding that diastolic dysfunction is apparent in very
young animals is also indicative of early compliance abnor-
mality contributing to abnormal myocardial mechanical and
structural modeling.
Diastolic dysfunction can arise from altered internal
cardiomyocyte conditions including high interbeat diastolic
Ca2+ levels that limit relaxation and/or increase sarcomere
structural stiffness.9,26 In the HHR, the elevated resting Ca2+
levels likely contribute to diastolic dysfunction, and the data
suggest that this may be attributed to increased SR Ca2+
“leakiness” mediated via CaMKII activation-induced ryanodine
receptor sensitization through hyperphosphorylation. Direct
CaMKII hyperphosphorylation of titin has also been associ-
ated with sarcomere stiffness.27 In this study, it was not
possible to detect a net change in total titin phosphorylation
state, suggesting that any CaMKII phosphorylation actions are
offset by other kinase signaling events. Titin isoform expres-
sion was not different in HHR—consistent with observations
in other rodent models of diastolic dysfunction.27
Arrhythmogenic vulnerability in various settings has been
associated with ectopic diastolic events of spontaneous SR
Ca2+ release. In the HHR the preserved SR “reloading”
capacity (through phospho-phospholamban-mediated SERCa2
disinhibition), in association with ryanodine receptor 2
sensitization (a combination of ryanodine receptor 2 hyper-
phosphorylation and SR load elevation), provides a substrate
for spontaneous SR Ca2+ release activity. Our ﬁndings show
that neither altered Na+/Ca2+ exchanger functional capacity
or disrupted T-tubule geometry are preconditions for occur-
rence of SR spontaneous Ca2+ release triggered arrhythmo-
genic events—that high Ca2+ operational levels independently
confer instability. Data from in vitro (intact cardiomyocytes)
and in vivo (ECG) experiments produced direct evidence of
HHR arrhythmogenic propensity, consistent with sudden
cardiac death–related HHR mortality during failure progres-
sion. This arrhythmogenic vulnerability evaluated in vitro may
be even more accentuated in vivo given that the HHR
neurohumoral milieu involves factors that differentially elevate
heart rate and may predispose to arrhythmia. In considering
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the demonstrated in vitro differences in HHR and NHR
cardiomyocyte performance, it is important to appreciate that
the in vivo disparity in heart rate is an additional major
consideration.
Myocardial ﬁbrosis/extracellular matrix remodeling also
plays a role in diastolic dysfunction.13 In the HHR, regions of
focal ﬁbrosis were evident, particularly prominent near the
interventricular septum, which were not present in the NHR.
Our histologic ﬁndings in HHR ventricular tissue might reﬂect
regional vulnerability to localized perimysial layer shear and
rupture28 more extensive in the septum conﬂuence, producing
areas of reparative ﬁbrosis associated with, and possibly
contributing to, the development of global ventricular stiffness.
Involvement of cardiomyocyte-speciﬁc inﬂammatory response
may also be involved—we have recently demonstrated
activation of lipocalin-2 mediated inﬂammatory pathways in
the HHR.29 A role for cardiomyocyte hypercontractility in
predisposing for mechanical shear damage is feasible. Indeed,
ﬁbrosis and slippage might change the mechanics of the
cardiac syncytium such that myocyte hypercontractility is not
translated to increased systolic function in vivo. In overview,
the etiologic processes that culminate in HHR HFpEF likely
have a long-term latent origin. We have previously reported
that hypertrophy in the HHR is linked with reduced cardiomy-
ocyte population at an early growth stage.16,17 This myocyte
deﬁcit apparently mediates compensatory hypertrophy and
hypercontractility of diminished myocyte endowment via a
mechano-transduction response (yet to be characterized).
Hypercontractility is associated with regions of tissue mechan-
ical vulnerability—myocyte rupture and ﬁbrotic replacement.
Thus, with progression toward failure, even while the surviving
cardiomyocyte population may be hypercontractile, the
remodeled tissue geometry and accumulating focal ﬁbrosis
undermines integrity. Overall, ejection fraction is relatively
conserved while function (primarily diastolic) is compromised.
Clinically, a range of earlier life cardiac stresses and genetic
factors could be expected to contribute to HFpEF predispo-
sition and ultimate disease emergence.
In summary, here we report the characterization of a new
model of HFpEF and provide the ﬁrst demonstration of
cardiomyocyte cellular pathophysiology underlying this
increasingly prevalent form of heart failure. Therapies that
have been largely successful in treatment of HFrEF have been
targeted at suppressing neurohumoral signaling axes involving
the renin-angiotensin-aldosterone system and b-adrenoceptors.3,14
Recently, evaluation of phosphodiesterase-5 inhibition also
reported lack of clinical improvement in HFpEF.30 While these
therapies may reduce morbidity in some HFpEF cohorts,
mortality reduction has not be achieved in trials to date.31
Now this investigation provides important mechanistic insight
into the contrasting cellular etiologies of HFpEF and HFrEF,
and represents a conceptual advance to be exploited for
targeted development of HFpEF-speciﬁc therapeutic interven-
tion. Based on this study’s novel ﬁndings, further studies of
the signaling pathways involved and the effects of systemic
secondary insults in shaping HFpEF failure development may
now be pursued. As a new preclinical platform, the HHR
provides a model for building multisystem pathology states
through additional interventions that capture the spectrum of
HFpEF phenotypes and comorbidities observed clinically. With
this new understanding of the cardiopathology mechanism,
there is potential opportunity for preclinical innovation in
responding to the HFpEF challenge.
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On request to the Corresponding author, the data, analytic methods, and study materials will be/have been 
made available to other researchers for purposes of reproducing the results or replicating the procedure. 
 
Development and maintenance of the Hypertrophic Heart Rat (HHR) and control Normal Heart Rat 
(NHR) strains 
A novel normotensive, hypertrophic rat strain has been generated through selection and cross breeding of 
Fischer 344 and Spontaneously Hypertensive Rat (SHR) strain progenitors.1 We had demonstrated 
previously that the SHR possessed genetic determinants of cardiac hypertrophy, independent of blood 
pressure.2 For the first 4 generations males and females were selected for the HHR line which exhibited 
elevated left ventricular echo dimensions relative to the corresponding mating pairs in the NHR line. Both 
lines were stabilized through 21 generations of in-breeding to achieve strain status.3 The control Normal 
Heart Rat (NHR) was co-derived from the same original F2 population. Thus, the Hypertrophic Heart Rat 
(HHR) and Normal Heart Rat (NHR) strains constitute genetically stabilized models for investigation of 
non-load induced hypertrophy, with natural disease history.  HHR and NHR genomic analysis has identified 
variants unique to each strain, including single nucleotide polymorphisms, insertions & deletions, and copy 
number variations. 3 Experiments were performed using male HHR and NHR at ages indicated. This study 
was confined to single sex evaluation and pooling of sex data avoided as previous studies have identified 
sex differences which will be further explored in additional studies. All animals were housed under a 12-
hour light/dark cycle with water and standard chow provided ad libitum. 
 
Echocardiography 
Cardiac structure and function were evaluated by transthoracic 2-dimensional B- and M-mode 
echocardiography (GE Vivid 9; 15mHz i13L linear array transducer) performed under light anesthesia 
(inhalation of isoflurane at 1.5%) ensuring temperature maintenance of animals. Acquisition and offline 
analysis was performed with GE EchoPac software. The parasternal short axis was utilized for systolic 
parameters (interventricular septum IVS, left ventricular posterior wall LVPW, left ventricular dimension 
LVID, fractional shortening FS, ejection fraction EF, heart rate HR), and mitral valve blood flow and tissue 
Doppler were measured in apical four chamber view for diastolic parameters (E/A, isovolumic relaxation 
time IVRT, mitral valve deceleration time MVDecT, E’/A’, E’/E). Normalized parameters for wall 
dimension indices were calculated for HHR by scaling measured values by the ratio of animal body weight 
relative to NHR mean. For each measurement at least three consecutive cycles were sampled.  
 
Electrocardiograms 
Electrocardiograms (ECG) were obtained under light anesthesia (inhalation of isoflurane at 1.5%) using 
external clip leads in standard configuration. The ECG signal was amplified (ADInstruments Animal Bio 
Amp), digitally acquired, filtered, displayed and analyzed using a MacLab data acquisition system.   
 
Hemodynamic measurements  
24-h blood pressure profiles in freely moving conscious rats were monitored over a continuous period of 
7 days by telemetry. Two weeks prior to recording, rats were implanted with blood pressure telemeters 
(model TA11PA-C40, Data Sciences International) in the abdominal aorta according to the method 
detailed by the supplier. Systolic and diastolic blood pressure, and mean arterial pressure were recorded 
as the reduced mean of a 10-s sampling interval every 10 min using data acquisition and analysis software 
(Data Sciences International, USA). As previously described4, to obtain hemodynamic measures by 
cardiac catheterization animals were anaesthetized with sodium pentobarbital (60mg/kg) and were 
intubated and ventilated using positive pressure with a tidal volume of 8 to 10% body weight at 70 
breaths/min using room air. A 2F miniaturized combined conductance catheter-micromanometer (Model 
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SPR-838 Millar instruments, Houston, TX) was inserted into the right carotid artery to obtain aortic blood 
pressure, and then advanced into the left ventricle until stable pressure-volume (PV) loops were obtained.  
Data were acquired under steady state conditions and during preload reduction. Using the pressure 
conductance data a range of functional parameters was then calculated (Lab Chart analysis software). 
These included end diastolic pressure (EDP), maximum rate of pressure change in the ventricle (+dP/dt 
max), minimum rate of pressure change in the ventricle (-dP/dt min) and the slope of the end diastolic 
pressure volume relationship (EDPVR). 
 
Histological Analysis of Myocardial Collagen Content 
Hearts were fixed in 10% formalin for histological analysis using picrosirius red as previously described.5 
Images were captured with brightfield microscopy using the Zeiss Imager D1, connected to a Zeiss 
AxioCam MRc5 colour camera and using AxioVision 40 version 4.7.1.0 acquisition software (Zeiss, 
Germany) with 10 images per section, from 2 sections per heart. Image analysis was performed using Image 
Pro Plus (V4.5.1, Media Cybernetics, MD, USA) in a ‘blinded’ manner. Briefly, images were converted to 
grey scale (255 pixel range), a pixel intensity histogram was assessed to determine the non-biased threshold 
point of collagen staining at 10% above the inflexion point in the histogram distribution. A binary map of 
collagen deposition was generated, from which collagen density was calculated and expressed relative to 
the total number of pixels in the area of interest. For each section, ten images per section positioned 
reproducibly at septal and ventricular free wall locations were analysed. In some images discrete areas of 
focal fibrosis were apparent.  For all images a value of total fibrosis (expressed % area) was determined 
and the mean value for all image fields calculated. For those images where discrete fibrotic foci were 
apparent, an additional determination of mean ‘interstitial fibrosis’ was made excluding these areas.  
 
Cardiomyocyte Structural Analysis by Tissue Section Confocal Microscopy 
For ultrastructural analysis to examine cardiomyocyte sarcomeric integrity, high resolution confocal 
microscopy was performed using fixed tissues labelled with the fluorescent marker wheat germ agglutinin 
(WGA, Alexa-594) to delineate cardiomyocyte T-tubule geometry as previously described.6,7 Fluorescent 
images of labelled tissue sections were recorded with a Zeiss LSM410 confocal microscope using a Zeiss 
63x NA 1.25 oil-immersion objective. Frequency analysis was used to assess the integrity of sarcolemmal 
T-tubular structure and the height of the peak at the sarcomere frequency of t-tubule labeling was used as 
one metric for integrity. The t-tubule images were converted to frequency space using the fast Fourier 
transform in the programming language IDL (Exelis). The height of the peak in the power spectrum 
corresponding to the sarcomere spacing (at ~0.5 µm-1) was then estimated by fitting a Gaussian (‘T 
power’). 
 
Cell Isolation and Cardiomyocyte Morphology 
Electromechanical performance of fura-2 loaded isolated cardiomyocytes obtained from HHR and NHR 
hearts at age ~30 weeks was evaluated (HHR 33.6±6.7 vs NHR 30.7±6.4 weeks), a timepoint selected as a 
disease progression stage immediately prior to emergence of premature mortality in HHR. NHR and HHR 
animals were weighed and then killed by decapitation under deep isoflurane anaesthesia. Hearts were 
blotted and wet heart weight measured. Single ventricular myocytes were isolated enzymatically using 
methods previously described.5,8 Briefly, hearts were removed and perfused retrogradely on a Langendorff 
apparatus with Ca2+-free bicarbonate-buffered physiological saline solution, maintained at 37oC, with the 
following composition (mM): NaCl, 118; KCl, 4.8; KH2PO4, 1.2; MgSO4, 1.2; NaHCO3, 25, glucose, 11. 
Following 20 minutes of 0.45 mg/ml collagenase (Worthington; Type II) perfusion, hearts were removed 
from the perfusion apparatus, the left ventricle was isolated, placed in a conical flask and myocytes were 
dispersed by gentle agitation. Fractions containing viable cells were re-suspended at room temperature in 
2-3 mls of HEPES-buffered physiological saline containing 1mM Ca2+ and were stored at room 
temperature. Cells were used within 8 hours. From each heart, 100 rod-shaped and regularly striated 
cardiomyocytes were selected randomly for length and width measurement at × 400 magnification using a 
Nikon inverted light microscope and calibrated eye piece as previously described.5,8 Cell volume was 
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calculated from the product of cell length and cell width using the previously described relationship between 
these parameters,9 in which cell volume is calculated as 7.59 × 10-3 pL/μm2 × cell area (μm2).  
 
Whole-Cell Patch Clamp 
I-Ca and I-NCX from NHR and HHR were measured in whole cell voltage clamp, using an Axopatch 200B 
patch-clamp amplifier (Axon Instruments, Foster City, CA) coupled to an A-D amplifier (Digidata 1200B, 
Axon Instruments) with 1-3 MΩ pipette resistances (glass type TW150F-3, World Precision Instruments, 
Sarasota, FL) as previously described.10  Prior to I-Ca and I-NCX measurements, membrane capacitance 
(Cm) was calculated from 5 mV hyperpolarizing and depolarizing steps applied from holding potential of 
-90 mV. 
 
For I-Ca measurements, the pipette contained (in mM): CsCl 100, TEA-Cl 20, MgATP 5, Li-GTP 0.2, 
EGTA 10, HEPES 10, and pH 7.4 adjusted with CsOH at room temperature (22-25oC). Cells were 
superfused with normal Tyrode’s solution containing (mM): NaCl 140, KCl 6, D-glucose 10, HEPES 5, 
MgCl2 1, CaCl2 1, and pH 7.4 adjusted with NaOH at room temperature. Once a successful ‘break in’ was 
obtained, the perfusion medium was switched to the modified normal Tyrode’s solution containing (mM): 
TEA-Cl 140, CsCl 6, to replace NaCl, KCl respectively and pH 7.4 adjusted with TEA-OH. Voltage step 
protocols with three holding potentials (HP) were applied to identify the calcium currents available at 
different potentials: -115 mV (all currents), -90 mV (substantially excluding I-Ca(TTX)) and -50 mV 
substantially excluding both I-Ca(T) and I-Ca(TTX). At each HP, test pulses were 400 ms depolarization and 
were made at test voltages ranging up to +60 mV, with steps of +10 mV increments (the interval between 
pulses was 2 s). 
 
For I-NCX measurements, the solutions were adapted from Pogwizd et al. 1999.11 The pipettes contained 
CsCl 45, Cs methanesulfonic acid 55, ATP-tris 10, GTP-tris 0.3, MgCl2 10.8, NaCl 14, CaCl2 2.21 (100 
nmol/L free Ca), 1,2-bis (2 amino phenoxy) ethane-N,N,N’,N’-tetra acetic acid (BAPTA) 5, Di-Br-1,2-bis 
(2 amino phenoxy) ethane-N,N,N’,N’-tetra acetic acid (Di-Br BAPTA) 5, HEPES 20. To isolate I-NCX the 
normal Tyrode’s solution was modified (CsCl 6 to replace KCl, CaCl2 2, BDM 30 and strophanthidin 10 
µmol/L to block Na/K-ATPase pump). To measure the I-NCX a combined voltage step and ramp protocol 
was applied.11,12 From an initial holding potential (HP) of -90 mV, the cell was depolarized to -45 mV (400 
ms) to activate and inactivate Na current. Then a step from -45 mV to 0 mV (200 ms) was used to activate 
and inactivate I-Ca. Finally, the voltage was stepped to +80 mV (200 ms) and ramped down to -140 mV 
(1000 ms) to assess I-NCX. The protocol was repeated in the presence of 5 mM NiCl2 to obtain Ni-sensitive 
I-Ca and I-NCX. To isolate I-NCX, the current traces were subtracted and the residual current measured 
during the +80 mV to -140 mV ramp was identified as I-NCX. Current analysis and curve fitting procedures 
were performed using Clampfit in pClamp8. For calculation of current density, currents were normalized 
by Cm. Current analysis and curve fitting procedures were performed using Clampfit in pClamp8. For 
calculation of current density, currents were normalized by Cm. 
 
Cardiomyocyte intracellular Ca2+ and Contractility Measurements 
Intracellular Ca2+ and cell length were measured simultaneously by microfluorimetry and edge detection 
(Ionoptix MA, USA) as previously described.13 Cells were loaded for 20 minutes with 2.5μM fura-2/AM 
(Molecular Probes, Eugene, Or, USA) at room temperature. They were placed in a chamber mounted on 
the stage of an Olympus IX51 inverted fluorescence microscope and superfused with 1.5 mM Ca2+ HEPES 
solution, 37oC at a rate of 2ml/min and stimulated to contract at 3Hz. Excitation light at 360nm and 380nm 
was provided by a 75-watt xenon lamp and filter wheel. Emitted fluorescence (510 nm) was recorded by a 
photomultiplier tube, with the output current converted to voltage and digitized for subsequent analysis 
using the interpolated numerator method. Background correction was undertaken at the completion of each 
cell recording and incorporated into analysis protocol. The following calcium parameters were measured: 
diastolic Ca2+, systolic Ca2+, amplitude of the Ca2+ transient and time constant of decay of the Ca2+ transient 
(tau). Phase-loop plots of single cardiomyocyte contraction cycles through shortening and lengthening were 
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constructed to provide an indication of shift in cardiomyocyte Ca2+ sensitivity as previously described.13 In 
a pilot experiment sarcoplasmic reticulum Ca2+ load level in myocytes immediately following steady state 
contraction was determined by rapid and brief exposure of myocytes to 10mM caffeine. The peak of the 
Ca2+ contracture transient generated through store discharge via opened SR Ca2+ release channels was 
measured.   
 
Cell length was measured using an edge detection system under basal conditions. For each contraction 
cycle, a range of normalized contractile parameters was automatically computed and averaged (% 
shortening (%S), time to peak shortening (Tm), maximum rate of shortening (mrs), maximum rate of 
lengthening (mrl) and time to cycle completion (Tf)).  Cardiomyocyte performance was evaluated: (i) under 
basal paced conditions (37oC, 3Hz, 1.5mM Ca2+), (ii) during a rest interval (37oC, 1.5mM Ca2+ 3Hz for 5 
mins, stimulator off 30 secs), and (iii) with different inotropic challenges (4 mM Ca2+, isoproterenol 10-
8M). All data were analyzed off-line using IonWizard (IonOptix, Milton, MA, USA). 
 
Immunoblotting 
Hearts were isolated and the blood flushed from the coronary vasculature with cold Krebs-Henseleit 
bicarbonate buffer (4oC). Ventricles were rapidly removed and snap frozen in liquid nitrogen. Ventricles 
were homogenized in 100mmol/L Tris-HCl, pH 7.0, phosphatase inhibitors NaF and Na3VO4 (at 5mmol/L 
and 0.5mmol/L respectively), and chelators EGTA and EDTA at 5mmol/L each (10mL buffer/g tissue) 
using an Ultra-Turrax tissue grinder (Crown Scientific, NSW, Australia). Non-fractionated homogenates 
were reconstituted in sodium dodecylsulphate (SDS) sample buffer. Samples were normalized for protein 
content. 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed, as previously described,14 using the 
Invitrogen XCell system (Invitrogen, VIC, Australia) using non-fractionated homogenate samples. After 
electrophoresis, proteins were transferred onto polyvinyl diflouride (PVDF) membranes using the XCell II 
blotter (Invitrogen, VIC, Australia). PVDF membranes were incubated in primary antibodies overnight at 
4˚C. Membranes were subsequently probed with the appropriate secondary antibody for 1 hour at room 
temperature and incubated in enhanced chemiluminescent reagent (Amersham ECL Plus, GE Healthcare) 
for 5 minutes. Protein bands were visualized with a Bio-Rad Chemi-XRS Imaging device, and band 
intensity was quantified using Quantity One imaging software (Bio-Rad). Representative Coomassie 
stained membranes (Fig S1B), confirmed equal loading of protein across all lanes in multiple gels used for 
each protein evaluation. In addition, dual calibrator control samples were included for all gels for every 
protein evaluated. Primary antibodies used in this study are tabulated (Fig S1A). For titin detection, protein 
bands and total phospho-protein levels were visualized using protein gel stains (Table S3). 
 
 
Statistical Analyses 
In general (unless otherwise stated) data are presented as mean ± SEM. Sample sizes were estimated based 
on previous findings reported using similar techniques when possible. Comparisons between two groups 
with normally distributed data were performed with Student’s unpaired t-test. Data from experiments with 
two groups assessed at multiple points were evaluated by a one-way analysis of variance (ANOVA) with 
repeated measures. Two-way ANOVA was used for evaluation of data groups comprising 2 factors. 
Correlation analyses were performed to determine the Pearson Coefficient within each strain and 
significance values evaluated. Data are shown depicting linear regression plots for each strain (SPSS c21.0; 
Graph Pad Prism V6). Data analysis was performed in a blinded manner. Survival (Kaplan Meier) data 
were analyzed by Log-rank Mantel-Cox test. Differences were considered significant at P < 0.05 ( SPSS 
v.21.0; Graph Pad Prism V6).  
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Table S1. Echocardiographic and hemodynamic (cardiac catheterization) analysis of 50 week and 
30 week HHR and NHR hearts. 
 
Parameter  
50 weeks 30 weeks 
NHR HHR NHR HHR 
Echocardiography 
IVSd (mm) 1.71 ± 0.04 2.20 ± 0.13* 1.76 ± 0.02 2.21 ± 0.06* 
LVPWd (mm) 1.89 ± 0.05 2.47 ± 0.23* 1.83 ± 0.08 2.62 ± 0.13* 
LVIDd (mm) 8.39 ± 0.12 9.21 ± 0.48 7.76 ± 0.12 8.87 ± 0.54 
LVIDs (mm) 5.01 ± 0.26 6.43 ± 0.36* 4.50 ± 0.20 5.96 ± 0.43* 
FS (%) 39.89 ± 2.2 30.35 ± 2.8* 42.14 ± 2.1 33.67 ± 1.1* 
EF (%) 74.6 ± 1.3 64.0 ± 3.8* 81.8 ± 1.6 73.2 ± 1.3* 
HR (bpm) 308 ± 6 352 ± 8* 312 ± 10 347 ± 7* 
E wave velocity (mm/s) 712 ± 54 1184 ± 121* 690 ± 34 1103 ± 65* 
A wave velocity (mm/s) 392 ± 23 885 ± 136* 383 ± 22 770 ± 87* 
E/A ratio (ratio) 1.86 ± 0.1 1.46 ± 0.14 1.83 ± 0.12 1.56 ± 0.14 
MV Dec T (ms) 61.1 ± 2.9 35.5 ± 4.5* 49.0 ± 3.8 26.8 ± 3.5* 
E’ velocity (mm/s) 43.4 ± 4.4 46.9 ± 10.6 44.5 ± 3.5 35.2 ± 5.2 
E/E’ (ratio) 16.9 ± 0.7 32.5 ± 4.6* 16.3 ± 1.0 33.3 ± 2.4* 
Hemodynamic      
LVEDP (mmHg) 10.6 ± 2.0 8.8 ± 1.9 N/A N/A 
+ dP/dt (mmHg/s) 6200 ± 528 7894 ± 478* N/A N/A 
- dP/dt (mmHg/s) 5048 ± 532 5751 ± 465 N/A N/A 
IVSd – normalized interventricular septum at diastole (BW adjusted), LVPWd – normalized left ventricular 
posterior wall at diastole (BW adjusted), LVIDd – left ventricular inner diameter at diastole, FS – fractional 
Shortening, EF – ejection fraction, HR – heart rate, MV DecT – mitral valve deceleration time, LVEDP – left 
ventricular end diastolic pressure, + dP/dt – maximal slope of the systolic pressure increment, - dP/dt – maximal 
slope of the diastolic pressure decrement.  (*p<0.05, 2-way ANOVA HHR vs NHR strain effect, n = 6 -10 
hearts/group) 
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Table S2. HHR & NHR Cardiac and cardiomyocyte morphology during progression to failure (30 
weeks). 
 
Parameter  NHR HHR 
CWI (mg/g) 3.40±0.1 (39) 4.50±0.3* (34) 
Myocyte Length (mm) 132.5±0.99 (22) 163.1±2.3* (16) 
Myocyte Width (mm) 29.7±0.3 (22) 35.8±0.7* (16) 
Myocyte Capacitance (pF) 302.1±15.0 (18) 384.5±14.2* (16) 
Myocyte Volume (pL) 29.84±0.4 (22) 44.34±1.3* (16) 
 
Significant elevation of cardiac weight and cardiac weight index in HHR, with increased cardiomyocyte 
size measured morphologically by dimensions, by computed volume and electrophysiologically (by 
capacitance). Calculated cardiomyocyte deficit of approx. 20% fewer cells/HHR heart (see Online 
Supplement regarding myocyte count calculation). (*p<0.05, Student’s t-test, N hearts n parentheses, 
myocyte dimensions measured from mean n=50 cells per heart). 
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Table S3. Gel staining summary information. 
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Figure S1. Telemetry blood pressure (20-30 weeks) and LV hemodynamic measurements (50 
weeks). 
 
 
 
A. Equivalent (normotensive) diurnal mean arterial pressure (MAP) states in HHR and NHR.  
(mean ± SD, n=6 HHR and NHR, age 20-30 weeks). B. Representative Pressure-Volume loops in NHR 
and HHR. C. Mean End Diastolic Pressure-Volume Relationship (EDPVR) measurements in HHR and 
NHR. For Panels B & C graphs show mean ± SEM, n=8-9 HHR and NHR, age 50 weeks. 
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Figure S2. Immunoblot primary antibody summary information & Coomassie stained membranes. 
 
 
 
A. Immunoblot primary antibody summary information for HHR and NHR. B. Representative Coomassie 
stained membranes for HHR & NHR confirming equal loading of protein across all lanes. 
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Figure S3. Longitudinal systolic & diastolic NHR & HHR functional measurements. 
 
 
 
A. Mean changes in ejection fraction over 50 wks for HHR and NHR. B. Mean values for diastolic 
function ratio E/E’ over 50 wks in HHR and NHR. (n=6-14 HHR and NHR, mean ± SEM) 
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Figure S4. Locational fibrotic mapping of HHR cardiac transverse sections (age 50 weeks). 
 
 
A. Schematic of transverse cardiac section indicating location of 10 image fields utilized for picrosirius 
analysis for all hearts. B. Mean relative fibrosis values from each of the ten locations, indicating more 
pronounced fibrosis at locations at/near position 7 and at position 1. (10 images per section, 2 sections per 
heart, N=5 hearts/group). 
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Figure S5. Titin-isoform composition and titin phosphorylation are unchanged in HHR (age 50 
weeks). 
 
 
 
 
A. Representative immunoblot analyses of titin protein expression and phosphorylation levels from HHR 
and NHR left ventricular tissues. B. Titin isoform composition is not different between HHR and NHR. 
C. Total titin protein expression levels are not different between HHR and NHR (N=5 hearts/group). 
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Figure S6. Enhanced sarcolemmal Ca2+ current density in HHR vs NHR.  
 
 
 
 
Voltage clamp protocol schematics, representative I-Ca current traces and mean normalized current-
voltage plots obtained for voltage step protocols from two holding potentials (HP): A. HP-115mV; B. HP-
50mV. Mean current densities (pA/pF) were significantly higher in the HHR at all holding potentials. 
(*p<0.05, 1-way ANOVA with repeated measures, n=12-18 cells/group). Graphs show mean±SEM, age 
20-30 weeks (pre-failure). 
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Figure S7. NCX1 protein expression is unchanged in HHR (age 20-30 weeks).  
 
A. Representative immunoblot analyses of NCX1 protein expression from HHR and NHR left ventricular 
tissues. B. NCX1 protein expression is not different between HHR and NHR. (*p<0.05, Student’s t-test. 
N=10 hearts/group). Graphs show mean±SEM. 
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Figure S8. NHR & HHR ECG parameters (age 50 weeks).  
 
 
 
A. Mean QRS interval significantly extended in HHR.  B. Mean QTc interval not different in HHR. 
(*p<0.05, Student’s t-test. N=8-12 sample periods/heart, duration 10 sec). Graphs show mean±SEM. 
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Figure S9. Increased cardiomyocyte SR Ca2+ load in HHR.  
 
 
A. SR load measurement protocol using caffeine (10mM) induced Ca2+ release preceded by 4Hz steady 
state stimulation. B. Caffeine transient amplitude expressed as mean fold change. (*p<0.05, Student’s t-
test, n=10-20 cells, for N = 2-3 hearts, mean±SEM). 
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